{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:52Z","timestamp":1792788292816,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["D43CA260658"],"award-info":[{"award-number":["D43CA260658"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"National Cancer Institute of National Institutes of Health","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}]},{"name":"Fogarty International Center of National Institutes of Health","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}]},{"name":"Fogarty International Center of National Institutes of Health","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}]},{"name":"Fogarty International Center of National Institutes of Health","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}]},{"name":"Fogarty International Center of National Institutes of Health","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Easy-to-use, rapid, scalable, high-throughput, and cost-effective HPV tests are urgently needed for low-resource settings. Atila Biosystems\u2019 high-throughput, cost-effective, and clinically validated ScreenFire HPV Risk Stratification (RS) assay identifies 13 high risk HPV (hrHPV) in 4 groups based on their oncogenic risk (i.e., HPV16, HPV18\/45, HPV31\/33\/35\/52\/58, and HPV51\/59\/39\/56\/68). The current standard format is subject to laboratory contamination, which is common for any molecular PCR test. To overcome this drawback, Atila has recently upgraded it into an innovative, contamination-free Zebra BioDome format. The contamination-free feature makes this novel assay format more suitable for large-scale community- and population-based cervical screening. This study evaluated the analytical performance of the Zebra BioDome format.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a study to test the analytical performance of Zebra Biodome format in comparison to the results of using the ScreenFire HPV RS assay standard format on Biorad CFX-96 real-time PCR instrument. We used overall agreement rate and unweighted kappa value to compare the performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall agreement for detection of hrHPV was 96.0% with unweighted kappa value 0.94 (95% confidence interval: 0.90\u20130.98). The agreement rates between hrHPV genotype 16 and risk stratification genotype group (HPV18\/45, HPV31\/33\/35\/52\/58, and HPV51\/59\/39\/56\/68) were all &gt;\u200997.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The innovative ScreenFire HPV RS assay Zebra BioDome format produced highly concordant results with the standard format. The shared features by the two assay formats, such as easy-to-use, high throughput, cost-appropriate, and no requirements for DNA extraction. The unique contamination-prevention feature along with no requirement of preparation of reagents make the Zebra BioDome format more suitable for large-scale HPV screening to reduce global cervical cancer burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13027-024-00622-2","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T06:57:15Z","timestamp":1732863435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Analytic performance of ScreenFire HPV RS assay Zebra BioDome format and its potential for large-scale population HPV screening"],"prefix":"10.1186","volume":"19","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godwin","family":"Imade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alani S.","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Anorlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Garcia-Bedoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria I.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeezu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoudou","family":"Maiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demirkan B.","family":"Gursel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiene S.","family":"Sagay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folasade T.","family":"Ogunsola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"issue":"3","key":"622_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"622_CR2","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjos\u00e9 S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191\u2013203.","journal-title":"Lancet Glob Health"},{"key":"622_CR3","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health. 2016;4:e609\u201316.","journal-title":"Lancet Global Health"},{"key":"622_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/cncr.30667","volume":"123","author":"W Small Jr","year":"2017","unstructured":"Small W Jr., Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: a global health crisis. Cancer. 2017;123:2404\u201312.","journal-title":"Cancer"},{"key":"622_CR5","doi-asserted-by":"publisher","first-page":"174550652110207","DOI":"10.1177\/17455065211020702","volume":"17","author":"J Huber","year":"2021","unstructured":"Huber J, Mueller A, Sailer M, Regidor PA. Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Womens Health (Lond). 2021;17:17455065211020702.","journal-title":"Womens Health (Lond)"},{"key":"622_CR6","unstructured":"World Health organization. New recommendations for screening and treatment to prevent cervical cancer: https:\/\/www.who.int\/news\/item\/06-07-2021-new-recommendations-for-screening-and-treatment-to-prevent-cervical-cancer (Last Time Accessed, June 2024)."},{"issue":"3","key":"622_CR7","doi-asserted-by":"publisher","first-page":"e25474","DOI":"10.1016\/j.heliyon.2024.e25474","volume":"10","author":"JD Siqueira","year":"2024","unstructured":"Siqueira JD, Alves BM, Castelo Branco ABC, Duque KCD, Bustamante-Teixeira MT, Soares EA, Levi JE, Azevedo E, Silva G, Soares MA. Comparison of four different human papillomavirus genotyping methods in cervical samples: addressing method-specific advantages and limitations. Heliyon. 2024;10(3):e25474.","journal-title":"Heliyon"},{"issue":"7","key":"622_CR8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ijc.34151","volume":"151","author":"KT Desai","year":"2022","unstructured":"Desai KT, Adepiti CA, Schiffman M, et al. Redesign of a rapid, lowcost HPV typing assay to support risk-based cervical screening and management. Int J Cancer. 2022;151(7):1142\u20139.","journal-title":"Int J Cancer"},{"issue":"2","key":"622_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijc.34698","volume":"154","author":"F Inturrisi","year":"2024","unstructured":"Inturrisi F, de Sanjos\u00e9 S, Desai KT, Dagnall C, Egemen D, Befano B, et al. A rapid HPV typing assay to support global cervical cancer screening and risk-based management: a cross-sectional study. Int J Cancer. 2024;154(2):241\u201350.","journal-title":"Int J Cancer"},{"issue":"1","key":"622_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13027-024-00585-4","volume":"19","author":"C Mungo","year":"2024","unstructured":"Mungo C, Guliam A, Chinula L, Inturrisi F, Msowoya L, Mkochi T, Jawadu S, de Sanjos\u00e9 S, Schiffman M, Tang JH, Smith JS. Comparison of the ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical precancer among women living with HIV in Malawi. Infect Agent Cancer. 2024;19(1):24.","journal-title":"Infect Agent Cancer"},{"issue":"6","key":"622_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/ajcp\/aqad181","volume":"161","author":"J Hou","year":"2024","unstructured":"Hou J, Belinson JL, Du H, Li C, Zhang W, Zhang L, Zhang Y, Qu X, Wu R. AmpFire HPV and ScreenFire RS HPV Validation Trial. Am J Clin Pathol. 2024;161(6):535\u201342.","journal-title":"Am J Clin Pathol"},{"key":"622_CR12","doi-asserted-by":"publisher","first-page":"834800","DOI":"10.3389\/fpubh.2022.834800","volume":"10","author":"J Musa","year":"2022","unstructured":"Musa J, Kim K, Zheng Y, Qu Y, Joyce BT, Wang J, et al. Accelerated epigenetic age among women with invasive cervical Cancer and HIV-Infection in Nigeria. Front Public Health. 2022;10:834800.","journal-title":"Front Public Health"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-024-00622-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T07:08:37Z","timestamp":1732864117000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-024-00622-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1186\/s13027-024-00622-2","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is covered under IRB approval (STU00207051) at Northwestern University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}